Clarence R Verhoef Net Worth

The estimated Net Worth of Clarence R Verhoef is at least $1.86 Milione dollars as of 14 February 2020. Clarence Verhoef owns over 6,382 units of Varian Medical Systems stock worth over $469,644 and over the last 12 years Clarence sold VAR stock worth over $1,386,786.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Clarence Verhoef VAR stock SEC Form 4 insiders trading

Clarence has made over 16 trades of the Varian Medical Systems stock since 2012, according to the Form 4 filled with the SEC. Most recently Clarence exercised 6,382 units of VAR stock worth $105,526 on 14 February 2020.

The largest trade Clarence's ever made was exercising 21,047 units of Varian Medical Systems stock on 16 October 2019 worth over $480,713. On average, Clarence trades about 1,947 units every 94 days since 2012. As of 14 February 2020 Clarence still owns at least 28,403 units of Varian Medical Systems stock.

You can see the complete history of Clarence Verhoef stock trades at the bottom of the page.

What's Clarence Verhoef's mailing address?

Clarence's mailing address filed with the SEC is C/O VAREX IMAGING CORP, 1678 S. PIONEER ROAD, SALT LAKE CITY, UT, 84104.

Insiders trading at Varian Medical Systems

Over the last 22 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin e Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.

What does Varian Medical Systems do?

Complete history of Clarence Verhoef stock trades at Varex Imaging Corp e Varian Medical Systems

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys